Other clinical efficacy endpoints
liver lesion
DISEASE PROGRESSION, DISEASE, TUMOR PROGRESSION
By RECIST criteria, one patient had a partial response in a liver lesion after 8 weeks of therapy. This was accompanied by a decrease in SUVmax below baseline. However, after 12 weeks of therapy there was evidence of disease progression, there were no patients who had clinical benefit as defined by stable disease for more than 24 weeks.The median time to tumor progression for the remaining 7 participants was 8 weeks. No patients needed to discontinue study therapy because of a requirement for opioid narcotics. Therapy was discontinued because of tumor progression in all cases. The overall survival of patients is as shown in Fig. Overall Survival by Kaplan-Meier estimate (days) of study patients